PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/7/2019 |
| Start Date: | October 2011 |
| End Date: | February 2014 |
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic
renal carcinoma, it is expected that this trial will establish the preliminary data needed to
apply for funding of a larger clinical investigation of the potential role of PET perfusion
imaging in management of renal carcinoma, and potentially other cancers.
renal carcinoma, it is expected that this trial will establish the preliminary data needed to
apply for funding of a larger clinical investigation of the potential role of PET perfusion
imaging in management of renal carcinoma, and potentially other cancers.
Inclusion Criteria:
- Ability to understand and willingness to sign a witnessed, informed consent and
authorization for the release of health information.
- Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically
unresponsive to prior treatment or surgically unresectable and with metastases that
fall within the PET/CT field-of-view that can include the heart.
- Being considered for systemic therapy with Sunitinib
Exclusion Criteria:
- Women who are pregnant, breast-feeding, or of childbearing potential and not using
birth control
- Having no telephone or a reliable way in which study personal can contact them
- Subjects who are claustrophobic and cannot tolerate imaging procedures
- Subjects who weigh > 350 lb. (upper weight limit of scanner beds)
We found this trial at
1
site
Click here to add this to my saved trials
